EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte–endothelial proadhesive interactions

Joan D Beckman, Angelica DaSilva, Elena Aronovich, Aithanh Nguyen, Julia Nguyen, Geneva Hargis, David Reynolds, Gregory M Vercellotti, Brian Betts, David K Wood

Journal of Thrombosis and Haemostasis · 2023-05 · 21 (5) · 1366-1380

DOI: 10.1016/j.jtha.2023.01.027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023-05. Verfasst von Joan D Beckman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA. Electronic addres…. Hauptthemen laut MEDLINE: Janus Kinases, COVID-19. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, NHLBI NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Vascular activation is characterized by increased proinflammatory, pro thrombotic, and proadhesive signaling. Several chronic and acute conditions, including Bcr-abl-negative myeloproliferative neoplasms (MPNs), graft-vs-host disease, and COVID-19 have been noted to have increased activation of the janus kinase (JAK)-signal transducer and downstream activator of transcription (STAT) pathways. Two notable inhibitors of the JAK-STAT pathway are ruxolitinib (JAK1/2 inhibitor) and fedratinib (JAK2 inhibitor), which are currently used to treat MPN patients. However, in some conditions, it has been noted that JAK inhibitors can increase the risk of thromboembolic complications. OBJECTIVES: We sought to define the anti-inflammatory and antithrombotic effects of JAK-STAT inhibitors in vascular endothelial cells. METHODS: We assessed endothelial activation in the presence or absence of ruxolitinib or fedratinib by using immunoblots, immunofluorescence, qRT-PCR, and function coagulation assays. Finally, we used endothelialized microfluidics perfused with blood from normal and JAK2V617F+ individuals to evaluate whether ruxolitinib and fedratinib changed cell adhesion. RESULTS: We found that both ruxolitinib and fedratinib reduced endothelial cell phospho-STAT1 and STAT3 signaling and attenuated nuclear phospho-NK-κB and phospho-c-Jun localization. JAK-STAT inhibition also limited secretion of proadhesive and procoagulant P-selectin and von Willebrand factor and proinflammatory IL-6. Likewise, we found that JAK-STAT inhibition reduced endothelial tissue factor and urokinase plasminogen activator expression and activity. CONCLUSIONS: By using endothelialized microfluidics perfused with whole blood samples, we demonstrated that endothelial treatment with JAK-STAT inhibitors prevented rolling of both healthy control and JAK2V617F MPN leukocytes. Together, these findings demonstrate that JAK-STAT inhibitors reduce the upregulation of critical prothrombotic pathways and prevent increased leukocyte-endothelial adhesion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus KinasesCOVID-19HumansSignal TransductionEndothelial CellsSTAT Transcription FactorsJanus Kinase 2LeukocytesNitrilesPyrazolesPyrimidines

Stichwörter der Autor:innen

endotheliumjanus kinase inhibitorsmyeloproliferative neoplasmthrombosistissue factor

Substanzen

Janus KinasesSTAT Transcription FactorsJanus Kinase 2ruxolitinibNitrilesPyrazolesPyrimidines

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA. Electronic address: beckm092@umn.edu.
  • Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Biomedical Engineering, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Förderung

  • NCATS NIH HHS
  • NHLBI NIH HHS
  • National Center for Advancing Translational Sciences
  • University of Illinois at Chicago
  • American Heart Association
  • American Society of Hematology
  • Astellas Pharma US
  • National Institutes of Health

Zitieren

APA

Beckman, J. D., DaSilva, A., Aronovich, E., Nguyen, A., Nguyen, J., Hargis, G., Reynolds, D., Vercellotti, G. M., Betts, B., & Wood, D. K. (2023). JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte–endothelial proadhesive interactions. Journal of Thrombosis and Haemostasis, 21(5), 1366-1380. https://doi.org/10.1016/j.jtha.2023.01.027

Vancouver

Beckman JD, DaSilva A, Aronovich E, Nguyen A, Nguyen J, Hargis G, et al. JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte–endothelial proadhesive interactions. Journal of Thrombosis and Haemostasis. 2023;21(5):1366-1380. doi:10.1016/j.jtha.2023.01.027

BibTeX
@article{Beckman2023,
  author = {Beckman, Joan D and DaSilva, Angelica and Aronovich, Elena and Nguyen, Aithanh and Nguyen, Julia and Hargis, Geneva and Reynolds, David and Vercellotti, Gregory M and Betts, Brian and Wood, David K},
  title = {JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte–endothelial proadhesive interactions},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2023},
  volume = {21},
  number = {5},
  pages = {1366--1380},
  doi = {10.1016/j.jtha.2023.01.027}
}
Kostenlos starten →